Kpderm 5G Cream is a topical formulation combining Ketoconazole (2% w/w), Clioquinol (Iodochlorhydroxyquin) (1% w/w), Tolnaftate (1% w/w), Neomycin (0.1% w/w), and Clobetasol (0.05% w/w), designed for the treatment of mixed fungal, bacterial, and inflammatory dermatoses. Ketoconazole, a broad-spectrum antifungal agent, inhibits ergosterol synthesis, disrupting fungal cell membrane integrity. Clioquinol exhibits antifungal and antibacterial properties, effective against various superficial infections. Tolnaftate is an antifungal that impedes fungal growth by inhibiting squalene epoxidase, thereby preventing ergosterol synthesis. Neomycin, an aminoglycoside antibiotic, targets susceptible Gram-negative and some Gram-positive bacteria by inhibiting protein synthesis. Clobetasol propionate, a potent corticosteroid, provides anti-inflammatory, antipruritic, and vasoconstrictive effects, reducing erythema, swelling, and itching associated with dermatoses. The synergistic combination in Kpderm 5G Cream offers comprehensive management of complex skin infections with inflammatory components, such as tinea, candidiasis, bacterial superinfections, and eczema with secondary infection. It is intended for topical use only and should be applied as directed by a healthcare professional. Prolonged use or misuse may lead to adverse effects including skin atrophy, resistance development, or systemic absorption. Caution is advised in patients with hypersensitivity to any component, and use is contraindicated in viral or tuberculous skin infections.